[Orthopaedic implant-associated infections: Update of antimicrobial therapy]

Enzyme-Responsive Nanoparticles and Coatings Made from Alginate/Peptide Ciprofloxacin Conjugates as Drug Release System

Infection-controlled release of antibacterial agents is of great importance, particularly for the control of peri-implant infections in the postoperative phase. Polymers containing antibiotics bound via enzymatically cleavable linkers could provide access to drug release systems that could accomplish this. Dispersions of nanogels were prepared by ionotropic gelation of alginate with poly-l-lysine, which was conjugated with ciprofloxacin as model drug via a copper-free 1,3-dipolar cycloaddition (click reaction). The nanogels are stable in dispersion and form films which are stable in aqueous environments. However, both the nanogels and the layers are degraded in the presence of an enzyme and the ciprofloxacin is released. The efficacy of the released drug against Staphylococcus aureus is negatively affected by the residues of the linker. Both the acyl modification of the amine nitrogen in ciprofloxacin and the sterically very demanding linker group with three annellated rings could be responsible for this. However the basic feasibility of the principle for enzyme-triggered release of drugs was successfully demonstrated.

Conversion From Knee Arthrodesis Back to Arthroplasty: A Particular Challenge in Combination With Fungal Periprosthetic Joint Infection

A 58-year-old female treated at an outside facility with knee arthrodesis due to persistent periprosthetic joint infection fulfilled all prerequisites for a conversion back to arthroplasty, as part of a 2-stage revision. Owing to the detection of Candida parapsilosis, the treatment concept was converted to a three-stage procedure. A scheduled spacer exchange with additional amphotericin B-loaded polymethylmethacrylate was conducted as an intermediate revision before reimplantation. Conversion in the setting of fungal periprosthetic joint infection presents a challenge, and successful treatment hinges on the use of proper antifungal and antimicrobial protocols, advanced surgical techniques, and a multidisciplinary team approach. At the 3-year follow-up, successful infection eradication as measured by the Delphi-based consensus definition was achieved with a range of motion of 0°-100°.

The direct anterior approach: treating periprosthetic joint infection of the hip using two-stage revision arthroplasty

BACKGROUND

Either one- or two-stage revision arthroplasties can be used for the treatment of chronic periprosthetic joint infection (PJI) after total hip arthroplasty (THA). We report our results following two-stage revision surgery performed through the direct anterior approach (DAA) interval using a custom-made articulating spacer.

METHODS

Between 2009 and 2014, 49 patients (49 consecutive procedures) had surgery through either a DAA or extended DAA approach. Each patient received perioperative intravenous administration of antibiotics. A custom-made spacer was implanted after explanting cup and stem and following extensive debridement. Broad-spectrum antibiotics were administered during the immediate perioperative period and then adjusted according to the infecting organism. Complication rates and eradication rates were observed. WOMAC patient assessments were administered preoperatively and one-year postoperatively.

RESULTS

Of the 49 study patients, five had a recurrence of the infection after the second-stage revision, five had a proximal periprosthetic fracture during the first stage procedure and one patient had a transient femoral nerve palsy that resolved fully within the first postoperative year. 30 different microorganisms were identified on intraoperative specimens. The average time between first and second stage procedure was 65.7 days (range 21-132 days). Eradication of infection was defined as healed wound without fistula, no drainage, no recurrence of the infection, no subsequent surgical intervention for persistent or perioperative infection after second stage revision and no long-term (> 6 months) antimicrobial suppression therapy. Eradication rate of infection in our study was 89.8%. Postoperative WOMAC scores improved significantly CONCLUSION: The preliminary clinical results for the custom-made spacer technique implanted through the DAA are promising. Therefore, we believe the DAA can be used safely as a standard operative approach for two-stage revision procedures.

Dalbavancin for treatment of implant-related methicillin-resistant Staphylococcus aureus osteomyelitis in an experimental rat model

Dalbavancin is a new semisynthetic lipoglycopeptide with improved antimicrobial activity against various gram-positive pathogens. It demonstrates an extensive plasma half-life which permits outpatient parenteral antimicrobial therapy with weekly intervals and might therefore be an excellent treatment alternative for patients requiring prolonged antimicrobial therapy. The present study investigated dalbavancin monotherapy in an experimental implant-related methicillin-resistant Staphylococcus aureus (MRSA) osteomyelitis model. A clinical MRSA isolate and a Kirschner-wire were inserted into the proximal tibia of anaesthetized Sprague-Dawley rats. Four weeks after infection 34 animals were treated over 4 weeks with either dalbavancin (20 mg/kg loading-dose; 10 mg/kg daily), vancomycin (50 mg/kg twice daily) or left untreated. Twenty-four hours after the last treatment dose tibial bones and Kirschner-wires were harvested for microbiological examination. Based on quantitative bacterial cultures of osseous tissue, dalbavancin was as effective as vancomycin and both were superior to no treatment. No emergence of an induced glycopeptide-/lipoglycopeptide- resistance was observed after a treatment period of four weeks with either dalbavancin or vancomycin. In conclusion, monotherapy with dalbavancin was shown to be as effective as vancomycin for treatment of experimental implant-related MRSA osteomyelitis in rats, but both antimicrobials demonstrated only limited efficacy. Further studies are warranted to evaluate the clinical efficacy of dalbavancin for the treatment of periprosthetic S. aureus infections.

Salvaging cochlear implant after wound infection: Well worth a try

BACKGROUND

Cochlear implant (CI)-related wound infections are known to happen even years after the implant procedure and present a challenging clinical situation. Due to the formation of biofilm on the implant surface such infections are difficult to eradicate. Invariably explantation of the device is required for wound healing.

METHOD

A 10-year-old patient presented with recurrent CI-related wound infection 8 years after implantation. The implant was salvaged with wound debridement and treating it with tea tree oil which is known for its biofilm eradicating properties. It was then covered with double layer of vascularised soft tissue. Combination of intravenous vancomycin and oral rifampicin known for their efficacy in biofilm-related infection was also used.

RESULTS

The implant could be salvaged using this novel technique of treating the implant with a biofilm eradicating agent, wound debridement, double layer vascularised soft tissue cover, and long-term antibiotics.

CONCLUSION

Agents having anti-biofilm activity when used in conjunction with surgical debridement and judicious antimicrobial therapy can be used for salvaging the implant and limiting the morbidity associated with these infections.

CD15 focus score: Infection diagnosis and stratification into low-virulence and high-virulence microbial pathogens in periprosthetic joint infection

INTRODUCTION

The aim of the work was to validate the CD15 focus score for the infection pathology of periprosthetic joint infection in a large group and to clarify whether a stratification into low-virulence and high-virulence microbial pathogens is possible by means of the CD15 focus score (quantification of CD15 positive granulocytes).

METHODS

The histopathology of 275 synovial tissue samples taken intraoperatively during revision operations (n=127 hip, n=141 knee, n=2 shoulder, n=5 ankle) was evaluated according to the SLIM consensus classification (SLIM=synovial-like interface membrane). Neutrophilic granulocytes (NG) were quantified by the CD15 focus score on the basis of the principle of focal maximum infiltration (focus) with evaluation of one field of vision (about 0.3mm²). The quantification values were compared with the microbiological diagnoses taking into consideration the virulence groups of low-virulence and high-virulence microbial pathogens and mixed infection.

RESULTS

The patients with positive microbiological findings (n=160) had significantly (p<0.001, Mann-Whitney U test) higher CD15 focus score values than patients with negative microbiological findings (n=115), the cut-off value being 39 cells per high power field (HPF). The CD15 focus score values of low-virulence microbial pathogens (n=94) were significantly lower (p<0.001, Mann-Whitney U test) than the values of high-virulence microbial pathogens (n=55), the cut-off value being 106 cells per HPF. Based on the microbiological diagnosis the sensitivity with respect to a microbial infection is 0.91, the specificity 0.92 (PPV=0.94; NPV=0.88; accuracy: 0.92; AUC=0.95). Based on the differentiation of the CD15 focus score values between low-virulence and high-virulence microbes the sensitivity is 0.70 and the specificity 0.77 (PPV=0.63; NPV=0.81; accuracy=0.74; AUC=0.74).

CONCLUSION

As a result of the high sensitivity and specificity, the easy to use CD15 focus score is a diagnostically valid score for microbial periprosthetic infection. A differentiation between low-virulence and high-virulence microorganism of sufficiently high diagnostic quality is additionally possible as a result of the defined quantification of CD15 positive granulocytes (the CD15 focus score) histopathological diagnosis of microbial infections is possible, which on the one hand supports the microbiological diagnosis and on the other hand by the stratification into low-virulence and high-virulence microbial pathogens could represent an additional basis for a pathogen-specific antibiotic treatment in the event of unclear constellations of findings.

[Not Available]

Zusammenfassung. Mit stetig steigender Häufigkeit endoprothetischer Eingriffe nimmt auch die Bedeutung der damit vergesellschafteten Revisionschirurgie zu. Die Gelenksprothesen-Infektion ist hierbei eine der schwerwiegendsten Komplikationen, die zur Erlangung eines bestmöglichen Behandlungsergebnisses eine differenzierte Diagnose- und Therapiestrategie erfordert. Anamnese, klinische Untersuchung, Laborkontrollen, Radiologie (konventionelle und spezialisierte), Gelenkspunktion sowie Mikrobiologie und Histologie liefern entscheidende Hinweise zur Diagnosestellung als unabdingbare Voraussetzung zur Erstellung und Einleitung des entsprechenden Therapiekonzeptes. Insbesondere die Abgrenzung zwischen aseptischen und septischen Prothesenlockerungen ist schwierig und erfordert ein differenziertes und interdisziplinäres Vorgehen. Die kurative Behandlungsstrategie ist abhängig von: Dauer der Symptome, Latenz seit Primärimplantation, Keimspektrum, Antibiogramm und Weichteilverhältnissen und umfasst prothesenerhaltende Strategien bei nicht gelockerter Prothese, reizlosen Weichteilen und Abwesenheit von Problemkeimen, bis hin zum kompletten ein- oder zweizeitigen Prothesenwechsel bei einer chronischen Infektion. In diesem Beitrag werden die aktuellen Management-Konzepte der Gelenksprothesen-Infektionen diskutiert.

[Management of periprosthetic infections of the knee]

Endoprosthetic replacement is one of the most successful operations in current medicine. As the implantation of knee prostheses increases, the number of periprosthetic infections is also rising. In case of painful or early loosening of the prosthesis an infection should be excluded by joint aspiration. Retention of the prosthesis with change of mobile parts is possible only in acute infections (< 4 weeks after surgery or duration of symptoms of <3 weeks in the case of hematogenous infection), if the prosthesis is stable, the soft tissue is intact, and no difficult-to-treat pathogens were found. In other cases a one- or two-stage prosthesis exchange should be performed. In a two-stage exchange, a short interval of 2-3 weeks is possible, if biofilm-active treatment is available. Rifampin should be used targeted (after isolation of the pathogen) and only in combination with another efficient antibiotic. In this article the current management concepts of periprosthetic infection of the knee are discussed.